Amelia Langston is an Oncology physician affiliated with Emory University. OpenAlex indexes 349 publications with 13,736 citations (h-index 53); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1365 Clifton Rd NE
Atlanta, GA 303221013
Telephone
404-778-1900Registry record last updated 8 Jul 2007.
Clinical trials
- Allogeneic Cell Therapy for Adults With Hematologic Malignancies
Sponsor: Emory University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ModernaTX, Inc.Program year20244 payments
- National Marrow Donor ProgramProgram year20242 payments
- ModernaTX, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
41.7%Kinase inhibitor24.8%Jakafi65%Imbruvica16%Iclusig11%Sirolimus7%Part D<11 patientsSelective immunosuppressants8.3%Rezurock100%Part D<11 patients+ 4 more classes in this area
Anti-infectives
32.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor11.9%Valacyclovir100%Part D≥23 patientsCytomegalovirus DNA Terminase Complex Inhibitor7%Prevymis100%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
8%Proton pump inhibitor3.8%Pantoprazole Sodium100%Part D≥12 patientsCorticosteroid2.5%Prednisone100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
Journal of Clinical Oncology
2021 - Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta‐analysis
Journal of Thrombosis and Haemostasis
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Guyton, MD
Emory University
Keith Delman, MD
Emory University
Paolo Raggi, MD
Emory University
Monica Farley, MD
Emory University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”